NOVAREMED-AG
5.3.2019 18:00:09 CET | Business Wire | Press release
The Board of Directors of Novaremed AG, a Swiss clinical-stage biopharmaceutical company, is pleased to announce the appointment of Nicholas Draeger as the new CEO. Nicholas will assume the role effective immediately. Former CEO and Founder, Eli Kaplan, will take a new role in the company to support the company’s further development of its lead asset and expansion of its drug pipeline.
“We are delighted to welcome Nicholas as the new CEO of Novaremed AG. His extensive experience in building and leading teams will be key to successful further development of Novaremed’s lead asset and the company itself. On behalf of the Board, I like to thank Eli for successfully building Novaremed through the past years and for leading the company through a period of significant change. His extensive knowledge of the lead asset will be an invaluable resource and support for the further development of the company.”, said Harry Welten, Chairman of the Board of Novaremed AG.
Nicholas Draeger, 53, has over 25 years of experience spanning the pharmaceutical, equity brokerage, investment management and processed food industries. He started his pharmaceutical career with research and global business development roles at Roche and Recordati. Following which, he joined Credit Agricole Indosuez Cheuvreux, a leading pan-European broker as Head of Biotechnology research. His healthcare portfolio management roles followed thereafter, first as a Portfolio Manager at BB Biotech and then as a Partner at Adamant BioMedical Investments, two of the leading European healthcare institutional investors. He has been leading as CEO, Nurevas International, a processed food company in Ghana, which he co-founded in 2011. Nicholas holds a BSc in Chemical Engineering from the University of Natal, South Africa, a PhD in BioChemical Engineering from the University of Cambridge, UK and an MBA from Warwick Business School, UK.
“I am delighted to have joined the Novaremed team. I look forward to working with the management team and board to continue to build on the excellent foundations that have been created to date. I would like to thank Eli for having founded Novaremed and helped guide this excellent company to this point.”, said Nicholas Draeger.
Eli Kaplan, Former CEO and Founder of Novaremed AG, commented: “I congratulate Nicholas for his new role and wish him the very best for leading Novaremed forward in successfully achieving its near- and long-term goals.”
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed is developing NRD.E1, an orally-active small molecule with a differentiated mechanism of action for the treatment of Diabetic Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DPN, expected to start in Q4 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005776/en/
Contact:
Subhasis Roy, Chief Operating Officer Tel: +41 79 2075715 Email: subhasis.roy@novaremed.com Web: www.novaremed.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Appoints Sheng-FU Hsiao as CTOLeveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure2.3.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company’s 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302064873/en/ SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure SBC Medical is transitioning from a traditional labor-intensive management model to an AI-driven infrastructure to address structural challenges in the m
SIMO Expands Carrier Enablement Strategy to Power Resilient, Multi-Network Enterprise Fixed Wireless Access Deployments2.3.2026 13:00:00 CET | Press release
xSIM orchestration delivers cross-network performance and unified global FWA deployment. SIMO, a leader in innovative mobile connectivity solutions, today announced the expansion of its carrier enablement strategy to power resilient, multi-network enterprise Fixed Wireless Access (FWA) deployments for both primary and backup applications. SIMO will showcase its evolution to a carrier enablement platform powering enterprise-grade FWA at Mobile World Congress 2026, in the MediaTek booth (Hall 3, Booth 3D10). “The future of enterprise FWA is not single-network, it is intelligently orchestrated multi-network connectivity,” said Eric Plam, chief revenue officer at SIMO. “By combining AI-driven local network selection with centralized global control, carriers can deliver resilient connectivity at scale while unlocking recurring managed service revenue.” Through SIMO xSIM orchestration operating at both the device firmware layer and the cloud, SIMO enables intelligent multi-network selection,
Venture Global Announces LNG Purchase Agreement with Trafigura2.3.2026 12:02:00 CET | Press release
New 5-year agreement offers flexibility and diversification to LNG portfolio Today, Venture Global, Inc. (NYSE: VG) and Trafigura announced the execution of a new, binding agreement for the purchase of approximately 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026. This mid-term agreement offers greater flexibility to customers in the global LNG market and provides greater diversification for Venture Global’s LNG portfolio. “Trafigura is a global leader in LNG trading, and we are pleased to execute this mid-term LNG supply agreement with them to provide the market with flexible and reliable U.S. LNG,” said Venture Global CEO Mike Sabel. “Global energy demand is stronger than ever, and this is an important step in executing our strategy of adding more mid-term agreements, which will diversify the tenor of our LNG portfolio. Venture Global looks forward to helping ensure the world remains well-supplied in the sh
“AI Realized Through Display” … Samsung Display Showcases AI-Optimized OLED Technologies at MWC262.3.2026 10:58:00 CET | Press release
Introducing “Flex Magic Pixel™,” a panel-integrated privacy technology enabled by low-power, high-brightness LEAD™… Essential smartphone privacy for the AI era’s surge in personalized data usage “Thinner and tougher”… Foldable OLED durability proven with a golf putting challenge “Create your own K-pop concert”… MR experience equipped with 5,000 PPI RGB OLEDoS draws major attention New concept “edge devices” incorporating Samsung Display OLED’s unique free-form, low-power and high-resolution technologies unveiled – including the companion robot concept “Mini PetBot” and the interior décor item “AI Toy House” Spain’s Park Güell tile mosaics recreated through displays using 6.8-inch OLED and 27-inch QD-OLED, highlighting high color reproduction and bezel-less technology Eric Kim, Executive Vice President and Head of Mobile Strategic Marketing: “In the AI era, displays will evolve from simple viewing screens into intelligent interfaces that understand and respond to users and their surroun
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio2.3.2026 09:00:00 CET | Press release
Radiobotics to join Medimaps Group, creating a global provider of AI-driven musculoskeletal (MSK) medical imaging software The transaction is expected to close following receipt of Danish foreign direct investment (FDI) approval and other customary closing conditions Together, they will bridge the gap between preventative bone health and acute trauma diagnostics, offering an expanded portfolio across X-ray and DXA: Fracture detection, opportunistic bone fragility assessment, and fracture risk prediction The combined entity will have a commercial reach in 90 countries through a robust network of direct and partner channels Both organizations will maintain their established brands, supported by close R&D and commercial collaboration Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, and Radiobotics ApS, a leader in AI-powered MSK radiology solutions, today announced that they have entered into a strategic merger agreement. Closing of the transacti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom